Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
$34.52
<$0.01(<0.01%)
At close: 4:00 PM EST
$34.52
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.26 - $46.67
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.85M
Market Cap
$3.00B
Enterprise Value$3.01B
Total Cash (Recent Filing)$190.68M
Total Debt (Recent Filing)$64.99M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 07, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding86,995,480
10 Day Avg. Volume2,002,504
30 Day Avg. Volume1,854,433
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue19.00
Enterprise Value/Gross Profit19.55
Enterprise Value/Ebitda-66.55
Forecast
1Y Price Target
$54.17Price Target Upside56.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.19
Revenue Forecast (FY)$494.28M
Bulls Say, Bears Say
Bulls Say
Clinical And Commercial ExpansionPlanned open-label studies, a randomized Phase 3 program for a next-generation therapy, and management's salesforce expansion aim to broaden clinical indications and provider coverage, potentially enlarging future revenue opportunities.
Commercial Launch MomentumAccelerating prescription uptake and rising patient starts for Yutrepia across pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indicate growing market acceptance and support stronger-than-expected sales momentum.
PRINT Technology DifferentiationPRINT dry-powder inhaler technology delivers precise control of particle size and shape, improving aerosol delivery and tolerability versus conventional dry powder approaches and reinforcing Yutrepia's competitive positioning.
Bears Say
Competitive Device UncertaintyA partner's surprise announcement of a new inhaled treprostinil device without supporting clinical data increases competitive uncertainty and could weaken investor confidence in market share prospects.
Funding And Cash RunwayCash resources appear limited relative to growth ambitions, raising the possibility that additional financing could be required to support development and commercial expansion and that such financings could dilute shareholders.
Patent LitigationPending patent litigation over a key patent creates uncertainty around market exclusivity and could drive stock volatility depending on the legal outcome.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.26 and its highest was $46.67 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.00B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 05, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.227 by -$0.077.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.41.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 86,995,480 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.15 in its last earnings report, missing expectations of $0.227. Following the earnings report the stock price went up 0.407%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.17 (56.92% Upside)
$54.17 (56.92% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 69.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear evidence of rapid, profitable scale: robust Q4 sales growth, consecutive profitable quarters, meaningful cash generation, accelerating patient starts and prescriber adoption, and a pipeline of label- and market-expanding studies including a next-generation product. Risks highlighted include unresolved litigation, modest expected gross-to-net pressure as access expands, distributor inventory timing variability, and ongoing competitive entrants (oral agents and alternate inhaler formats). Management presented confident mitigation plans (expanded sales force, clinical transition studies, L606 development) and indicated operational cash funding for trials.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$54.17
▲(56.92% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
22.08% Insiders
7.59% Mutual Funds
4.49% Other Institutional Investors
56.37% Public Companies and
Individual Investors